AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read

Newcore Gold Ltd. (NCAU) Reports 1.16 g/t Au Over 41m at Enchi

Newcore Gold reported RC drilling results at Enchi’s Boin deposit, including 1.16 g/t Au over 41.0m, which may support future reserve growth and mine optimization. The results are part of a multi-year program to expand resources, with a 2026 PFS baseline excluding these findings.

Original reporting
tradingview.com
Published Oct 6, 2026, 10:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 10:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Newcore Gold Ltd. (NCAU) Reports 1.16 g/t Au Over 41m at Enchi — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The reported intercept could lead to an updated PFS, influencing valuation.

02

Market read

Fresh drilling data provides material information for investors in Newcore Gold and comparable junior miners.

03

What to watch

Potential permitting or financing constraints could limit project development.

Relevance 6/10Novelty 6/10Timing: today

Background

The Enchi project is a key asset for Newcore Gold, with ongoing drilling to expand its resource base.

Market effects

Sector

May boost sentiment for junior gold explorers in the region.

Regional

Limited to Canadian and US junior mining markets.

Global

Low global impact.

Counterpoint

What could challenge this read

Drill results may not translate into economic reserves without further validation.

Key entities

  • Company
    Newcore Gold Ltd.

    Junior gold miner reporting drilling results.

Read at source← All news

Related articles

SEP 17
$NCAUFMed

Newcore’s wide gold hit boosts Enchi plan in Ghana

Newcore Gold (TSXV: NCAU, US-OTC: NCAUF) reported significant gold intercepts at its Boin deposit in Ghana, including 69m at 2.59g/t. The findings could enhance the mine plan for its Enchi project. Shares rose 17% to 34¢. The company aims to secure a mining lease by year-end and complete an 80,000m drill program. According to a June study, Boin contains 429,000 oz. probable, 550,000 oz. indicated, and 178,000 oz. inferred gold.

northernminer.com2 min
AUG 7
$NCAUFMed

Newcore's Enchi study assesses a 5.5M-tonne annual mill

Newcore Gold filed an NI 43-101 technical report for the Enchi Gold Project in Ghana supporting a pre-feasibility study effective June 23, 2026. The base case targets a conventional open pit with 5.5 million tonnes per annum and carbon-in-leach processing using contract mining. The PFS is based on a March 18, 2026 resource estimate and excludes over 50,000 metres of ongoing drilling.

stocktitan.net4 min
OCT 23
$TEMHigh

Tempus AI Signs $192.5 Million Data Agreements with BMS and Pathos

Tempus AI secured $192.5M in data agreements with BMS and Pathos AI. BMS will pay $137.5M for oncology data and software by 2031. Pathos may pay up to $55M for neurology data and tools, with payments tied to data delivery. Tempus restricted certain records from third-party licensing. According to the company's SEC filing.

tradingview.com1 min
OCT 23
$IDYAHighAI 9/10

IDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer

IDEAYA Biosciences reported Phase 1 results for IDE849, showing antitumor activity in relapsed small cell lung cancer. Median overall survival was 17.4 months in second-line SCLC and 14.7 months across second-line and later-line patients. The confirmed response rate was 60.8% in second-line SCLC. IDEAYA plans Phase 3 trials. The stock closed at $36.12, up 1.83%, and is down 0.03% in premarket trading.

rttnews.com1 min
OCT 23
$BMYLow

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Pathos AI partnered with Bristol Myers Squibb and Tempus AI to develop AI tools for drug development in Alzheimer's and other neurological disorders. The company raised $237 million in a Series E funding round led by Bristol Myers, valuing it at $3 billion. Pathos will license data from Tempus for $55 million over five years and use its AI platform, Pathos Foundry, to study the dataset and design clinical trials. Bristol Myers gains non-exclusive access to Pathos Foundry.

finance.yahoo.com2 min
OCT 23
$TEMHighAI 9/10

Tempus AI, Inc. announced that it had entered into a series of agreements with Bristol-Myers Squibb Company and Pathos AI, Inc. to expand the use of Tempus’s…

Tempus AI, Inc. (TEM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal real-world data, data

SEC EDGAR 8-K2 min